BridgeMD
Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study.
EU CTIS ID: 2023-504150-35-00
What this study is testing
To evaluate effectiveness of a single oral dose of NEPA in terms of complete response (CR: no emesis, no rescue medication) in the overall phase (0-120h) at cycle 1 in chemotherapy-naïve patients with endometrial cancer receiving paclitaxel and carboplatin with or without immunotherapy.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject is at least 18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent.
- Subject has histologically or cytologically proven endometrial cancer.
- Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical practice and opinion of treating physician.
- Naive to chemotherapy.
You likely can't join if
- Patients will experience emesis within the 24 hours before receipt of 1 course of chemotherapy.
- Patients will be scheduled to radiation therapy to the abdomen or pelvis within 1 week before day 1 or between day 1 and 5.
- Patients will be scheduled to undergo bone marrow or stem-cell transplant.
- Chronic systemic corticosteroid use.
- Brain metastasis.
- Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder.
See the full eligibility criteria
- Subject is at least 18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent.
- Subject has histologically or cytologically proven endometrial cancer.
- Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical practice and opinion of treating physician.
- Naive to chemotherapy.
- Patients will experience emesis within the 24 hours before receipt of 1 course of chemotherapy.
- Patients will be scheduled to radiation therapy to the abdomen or pelvis within 1 week before day 1 or between day 1 and 5.
- Patients will be scheduled to undergo bone marrow or stem-cell transplant.
- Chronic systemic corticosteroid use.
- Brain metastasis.
- Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder.
- History or predisposition to cardiac conduction abnormalities, torsade des pointes or severe cardiovascular diseases.
- Subject is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study treatment.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.